Literature DB >> 31212294

Outcomes after Thrombectomy in Belfast: Mothership and Drip-and-Ship in the Real World.

Karen M Adams1, Paul A Burns2, Annemarie Hunter3, Ian Rennie2, Peter A Flynn2, Graham Smyth2, Patricia L Gordon4, Cathy E Patterson4, Patricia Fearon4, Enda L F Kerr4, M Ivan Wiggam4.   

Abstract

BACKGROUND: Mechanical thrombectomy has revolutionised the treatment of acute ischaemic stroke due to large vessel occlusion. It is well recognised that patients are more likely to benefit when reperfusion happens quickly, however, there is uncertainty as to how best to deliver this service.
OBJECTIVES: To compare outcomes of patients in Northern -Ireland who underwent thrombectomy via direct admission to the single endovascular centre (mothership [MS]) with those transferred from primary stroke centres (drip-and-ship [DS]).
METHODS: Analysis was conducted on the records of all patients who underwent thrombectomy from January 2014 to December 2017 inclusive. The primary outcome measure was 3 months functional independence (modified Rankin Score [mRS] 0-2). Secondary outcome measures were full recovery (mRS 0) at 3 months, symptomatic intracranial haemorrhage (sICH) rates and mortality rates.
RESULTS: Two hundred fourteen patients underwent thrombectomy (MS 124, DS 90). Patients in the MS group were older (median 73 vs. 70 years, p = 0.026), but there was no significant difference in baseline National Institutes of Health Stroke Scale (median 15 MS vs. 16.5 DS, p = 0.162) or thrombolysis rates (41.9% MS vs. 54.4% DS, p = 0.070) between the groups. Time from stroke onset to arrival at thrombectomy centre was shorter in the MS group (median 71 vs. 218 min, p < 0.001) but door to groin puncture time was shorter in the DS group (median 30 vs. 60 min, p < 0.001). There was no significant difference in 3 months functional independence (51.6% MS vs. 62.2% DS, p = 0.123), or in the secondary outcome measures of full recovery (21.8% MS vs. 12.2% DS, p = 0.071), sICH (MS 0.8%, DS 4.4%, p = 0.082) and mortality (MS 24.2%, DS 20.0%, p = 0.468).
CONCLUSIONS: Our analysis showed similar outcomes after thrombectomy in the MS and DS groups. For patients potentially eligible for thrombectomy, rapid access to the endovascular centre is essential to optimise both the number of patients treated and the outcomes achieved.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Acute stroke; Drip-and-ship; Endovascular treatment; Functional outcome; Thrombectomy

Mesh:

Year:  2019        PMID: 31212294     DOI: 10.1159/000500849

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

Review 1.  Acute ischemic stroke treatment model for Poland in the mechanical thrombectomy era - which way to go?

Authors:  Krzysztof Pawłowski; Artur Dziadkiewicz; Jacek Klaudel; Alicja Mączkowiak; Marek Szołkiewicz
Journal:  Postepy Kardiol Interwencyjnej       Date:  2022-04-11       Impact factor: 1.065

2.  Optimizing Patient Selection for Interhospital Transfer and Endovascular Therapy in Acute Ischemic Stroke: Real-World Data From a Supraregional, Hub-and-Spoke Neurovascular Network in Germany.

Authors:  Maria-Ioanna Stefanou; Vera Stadler; Dominik Baku; Florian Hennersdorf; Ulrike Ernemann; Ulf Ziemann; Sven Poli; Annerose Mengel
Journal:  Front Neurol       Date:  2020-12-04       Impact factor: 4.003

3.  A Neurodisparity Index of Nationwide Access to Neurological Health Care in Northern Ireland.

Authors:  Mark O McCarron; Mike Clarke; Paul Burns; Michael McCormick; Peter McCarron; Raeburn B Forbes; Luke V McCarron; Fiona Mullan; Ferghal McVerry
Journal:  Front Neurol       Date:  2021-02-12       Impact factor: 4.003

4.  Mechanical thrombectomy: can it be safely delivered out of hours in the UK?

Authors:  Jake Weddell; Emma Parr; Stacey Knight; Girish Muddegowda; Indira Natarajan; Jayan Chembala; Phillip Ferdinand; Nasar Ahmad; Zoltan Pencz; Saad Rana; Anushka Warusevitane; Changez Jadun; Sanjeev Nayak; Zafar Hashim; Albin Augustine; Julius Sim; Christine Roffe
Journal:  BMC Neurol       Date:  2020-09-01       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.